SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Angeli P, Wong F, Watson H, Gines P. Hyponatremia in cirrhosis: Results of a patient population survey. HEPATOLOGY 2006; 44: 15351542.
  • 2
    Biggins SW, Kim WR, Terrault NA, Saab S, Balan V, Schiano T, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 2006; 130: 16521660.
  • 3
    Porcel A, Diaz F, Rendon P, Macias M, Martin-Herrera L, Giron-Gonzalez JA. Dilutional hyponatremia in patients with cirrhosis and ascites. Arch Intern Med 2002; 162: 323328.
  • 4
    Yeates KE, Morton AR. Vasopressin antagonists: role in the management of hyponatremia. Am J Nephrol 2006; 26: 348355.
  • 5
    Castello L, Pirisi M, Sainaghi PP, Bartoli E. Hyponatremia in liver cirrhosis: pathophysiological principles of management. Dig Liver Dis 2005; 37: 7381.
  • 6
    Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355: 20992112.
  • 7
    Thuluvath PJ, Maheshwari A, Wong F, Yoo HW, Schrier RW, Parikh C, et al. Oral V2 receptor antagonist (RWJ-351647) in patients with cirrhosis and ascites: a randomized, double-blind, placebo-controlled, single ascending dose study. Aliment Pharmacol Ther 2006; 24: 973982.
  • 8
    Gines P, Wong F, Watson H, Ruiz del Arbol LR, Bilic A, Dobru D. Effects of a selective vasopressin V2 receptor antagonist, satavaptan (SR121463B) in patients with cirrhosis and ascites without hyponatremia. HEPATOLOGY 2006; 44: A691.
  • 9
    Wong F, Gines P, Watson H, Kujundzic M, Angeli P, Horsmans Y. Effects of a selective vasopressin V2 receptor antagonist, satavaptan (SR121463B) on recurrence of ascites after large volume paacentesis. HEPATOLOGY 2006; 44: A180.